The following is bad news for men in England with advanced prostate cancer. The rationale behind making this drug unavailable to men was cost. If anyone here in the US recommends we switch to the British system of health care, this should serve as a wakeup call against it. The therapy as described in the more »
The Prostate Cancer Foundation recently published a comprehensive patient guide. I may have sent this post before but if not see the following link.
I recently came across an excellent review on the pros and cons of prostate cancer surgery as published by the Prostate Cancer Research Institute (PCRI). I am linking the review. If you are contemplating surgery, please read it and discuss it with your surgeon. You might also want to verify the opinions expressed in this more »
A few nights ago, I could not sleep so I sat up and decided to read something light until I got sleepy. Instead a still small voice inside me suggested I use the time alone to talk to God in conversational prayer. As I often do after thanking Him for a number of blessings in more »
In early May, the United States Preventive Services Task Force (USPSTF) finalized its new prostate cancer screening recommendation, which upgrades its recommendation for men 55 – 69 years old to a C rating. While the updated rating is a step forward, many say it’s not enough. The decade-long message that discouraged men from getting tested has more »
We who struggle with various medical conditions are often either seeking guidance from God about specific decisions or awaiting results and answers to our prayers. In Psalm 130, the author writes about being in deep distress facing a situation that feels like the blackest of nights. He writes in verse one “out of the depths more »
Drugs targeting poly (ADP-ribose) polymerase (PARP) are helping patients battle back more effectively against cancer. An enzyme, PARP helps repair damaged DNA in cells, and while that’s a good thing in healthy people, it can be bad news for cancer patients. To prevent PARP from repairing DNA breaks in cancer cells, AstraZeneca developed Lynparza, a PARP inhibitor (PARPi) more »
The drug, TAK-700 (Ortoronel) and Phase 3 clinical trials have been described in a blog published on this website on June 3rd, 2011. TAK-700 is an oral, non-steroidal, androgen (e.g. testosterone) synthesis inhibitor. It is being developed by the Takeda Oncology Company affiliated with Millennium. They are sponsoring safety and efficacy clinical trials in men more »
Zero-the Project to End Prostate Cancer recently published an e mail manual for men newly diagnosed with prostate cancer and for their families. It can be found at the following link. Topics include prostate cancer basics, methods used in its diagnosis including genomic testing, interpretation of test results, choosing the right health care professionals and more »
On February 8th, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Zytiga® (abiraterone acetate) in combination with prednisone for the treatment of patients with metastatic high-risk hormone-sensitive prostate cancer (HSPC). The approval is based on Phase 3 data from the pivotal more »
As part of the Sermon on the Mount, Jesus spoke the following words from Matthew 6:25-30 about worry and anxiety, emotions and feelings most of us with prostate cancer can relate to. “Do not be anxious for your own life, what you shall eat, or what you shall drink; nor for your body as to more »
On Feb. 14th, the U.S. Food and Drug Administration approved apalutamide (Erleada®, previously called ARN-509) for the treatment of non-metastatic, castration (hormone)-resistant prostate cancer (CRPC). Apalutamide could be administered in a clinical setting wherein men who are being treated with androgen (hormone) deprivation therapy (ADT) see their PSA levels begin to rise, but no metastases more »
According to results just recently presented at the February 2018 Genitourinary Cancers Symposium in San Francisco, treatment with Xtandi® (enzalutamide) reduced the risk of metastasis or death in hormone-resistant prostate cancer (CRPC) patients whose cancer has not yet spread beyond the prostate, Pfizer and Japan-based Astellas Pharma recently announced. The Phase 3 PROSPER clinical trial more »
OncBioMune’s investigational cancer vaccine ProscaVax reduced tumor growth in 70% of prostate cancer patients included in a Phase 1a study. The immunotherapy candidate consists of a combination of the PSA protein (a hallmark of prostate cancer) with the cytokines — molecules produced by immune cells — interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF). The clinical trial (NCT02058680) is evaluating the safety more »
The Prostate Cancer Foundation recently published a 32-page guide containing diet recommendations for men living with prostate cancer. There is considerable discussion on plant-based foods, dietary fats, sugar, beverages and nutrients. See the following link for the guide.
For several weeks, I had been undergoing a cutting-edge, experimental cancer treatment. I firmly believed God had led me to this stage by a totally unexpected but logical pathway. My oncologist had also enthusiastically concurred with my choice. One of the few ways to determine therapeutic progress in this trial is by measuring one’s prostate more »
Zero-the project to end prostate cancer is sponsoring a webcast on advanced prostate cancer. The webcast is scheduled for Tuesday, December 19th at 7-8 PM. For registration and information, see the following link.
I personally know of two Vietnam era veterans who were exposed to Agent Orange during their military service; both contracted prostate cancer. Hence it was of interest that I read the following linked article from the Prostate Cancer Foundation describing long over-due efforts to study and determine the best prostate cancer diagnostic (as to aggressiveness) more »
HIGHLY RECOMMENDED: The Prostate Cancer Foundation (PCF) recently published (November 2017) an electronic patient guide which can be downloaded to your computer or obtained as a hard copy. Main topics include: 1) You and Prostate Cancer – General Information -Medical Basics; 2) For the Newly Diagnosed; 3) Treatment Options for Localized or Locally Advanced Prostate Cancer; more »
Adding Xtandi® (enzalutamide) to hormone therapy reduces the risk of cancer spreading in patients with non-metastatic, hormone-resistant prostate cancer (CRPC), new Phase 3 trial data shows. Additional results were announced by Pfizer and Astellas Pharma, the drug developers. “Many prostate cancer patients who initiate hormone therapy will experience disease progression illustrated by a rising PSA level, and currently, more »